NASDAQ:VCEL Vericel (VCEL) Stock Price, News & Analysis $42.01 +0.78 (+1.89%) Closing price 04:00 PM EasternExtended Trading$42.01 0.00 (0.00%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Vericel Stock (NASDAQ:VCEL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vericel alerts:Sign Up Key Stats Today's Range$40.55▼$42.3750-Day Range$38.60▼$58.6552-Week Range$37.76▼$63.00Volume437,192 shsAverage Volume390,910 shsMarket Capitalization$2.11 billionP/E Ratio700.28Dividend YieldN/APrice Target$60.86Consensus RatingBuy Company OverviewVericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.Read More… Remove Ads Vericel Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreVCEL MarketRank™: Vericel scored higher than 48% of companies evaluated by MarketBeat, and ranked 389th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingVericel has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVericel has only been the subject of 4 research reports in the past 90 days.Read more about Vericel's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth214.29% Earnings GrowthEarnings for Vericel are expected to grow by 214.29% in the coming year, from $0.14 to $0.44 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vericel is 700.28, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.47.Price to Earnings Ratio vs. SectorThe P/E ratio of Vericel is 700.28, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.73.Price to Book Value per Share RatioVericel has a P/B Ratio of 8.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Vericel's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.51% of the float of Vericel has been sold short.Short Interest Ratio / Days to CoverVericel has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Vericel has recently increased by 12.11%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVericel does not currently pay a dividend.Dividend GrowthVericel does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.51% of the float of Vericel has been sold short.Short Interest Ratio / Days to CoverVericel has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Vericel has recently increased by 12.11%, indicating that investor sentiment is decreasing significantly. News and Social Media2.7 / 5News Sentiment0.79 News SentimentVericel has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Vericel this week, compared to 6 articles on an average week.MarketBeat Follows4 people have added Vericel to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Vericel insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,724,548.00 in company stock.Percentage Held by InsidersOnly 5.20% of the stock of Vericel is held by insiders.Read more about Vericel's insider trading history. Receive VCEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat's FREE daily newsletter. Email Address VCEL Stock News HeadlinesInsider Selling: Vericel Co. (NASDAQ:VCEL) CEO Sells 24,850 Shares of StockApril 12 at 5:37 AM | insidertrades.comVericel Co. (NASDAQ:VCEL) CEO Sells $1,217,381.76 in StockMarch 15, 2025 | insidertrades.comHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.April 15, 2025 | Brownstone Research (Ad)Vericel price target lowered to $60 from $63 at BTIGApril 15 at 8:07 PM | markets.businessinsider.comVericel (NASDAQ:VCEL) Price Target Lowered to $51.00 at Truist FinancialApril 13 at 1:57 AM | americanbankingnews.comVericel price target lowered to $51 from $61 at TruistApril 11, 2025 | markets.businessinsider.comVericel is Now Oversold (VCEL)April 3, 2025 | nasdaq.comAn Intrinsic Calculation For Vericel Corporation (NASDAQ:VCEL) Suggests It's 47% UndervaluedMarch 27, 2025 | finance.yahoo.comSee More Headlines VCEL Stock Analysis - Frequently Asked Questions How have VCEL shares performed this year? Vericel's stock was trading at $54.91 at the start of the year. Since then, VCEL stock has decreased by 23.5% and is now trading at $42.01. View the best growth stocks for 2025 here. How were Vericel's earnings last quarter? Vericel Co. (NASDAQ:VCEL) released its earnings results on Thursday, August, 1st. The biotechnology company reported ($0.10) EPS for the quarter, hitting the consensus estimate of ($0.10). Vericel's revenue was up 14.8% on a year-over-year basis. Read the conference call transcript. Who are Vericel's major shareholders? Top institutional shareholders of Vericel include Congress Asset Management Co. (2.95%), Rhumbline Advisers (0.28%), GAMMA Investing LLC (0.26%) and Handelsbanken Fonder AB (0.04%). Insiders that own company stock include Dominick Colangelo, Jonathan Mark Hopper, Paul K Wotton, Robert L Md Zerbe, Joseph Anthony Mara Jr, Steven C Gilman, Jonathan Siegal, Michael Halpin and Sean C Flynn. View institutional ownership trends. How do I buy shares of Vericel? Shares of VCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vericel own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vericel investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Palo Alto Networks (PANW) and Netflix (NFLX). Company Calendar Last Earnings8/01/2024Today4/15/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VCEL CIK887359 Webwww.vcel.com Phone(617) 588-5555Fax617-588-5554Employees300Year Founded1989Price Target and Rating Average Stock Price Target$60.86 High Stock Price Target$67.00 Low Stock Price Target$51.00 Potential Upside/Downside+44.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)$0.18 Trailing P/E Ratio700.45 Forward P/E Ratio300.14 P/E GrowthN/ANet Income$-3,180,000.00 Net Margins1.56% Pretax Margin2.05% Return on Equity1.48% Return on Assets0.96% Debt Debt-to-Equity RatioN/A Current Ratio4.61 Quick Ratio4.23 Sales & Book Value Annual Sales$237.22 million Price / Sales8.88 Cash Flow$0.01 per share Price / Cash Flow3,081.95 Book Value$4.73 per share Price / Book8.88Miscellaneous Outstanding Shares50,136,000Free Float46,791,000Market Cap$2.11 billion OptionableOptionable Beta1.61 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:VCEL) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vericel Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vericel With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.